双翼原创

Double Wings Original is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapies. The company utilizes its proprietary Twin-Wing platform to engineer dual-targeting and armored cell therapies designed to overcome antigen escape and the immunosuppressive tumor microenvironment. Their primary research focus encompasses both hematological malignancies and difficult-to-treat solid tumors, such as liver cancer. The lead programs include a CD19/CD22 dual-targeting CAR-T and a GPC3-targeted therapy for hepatocellular carcinoma. By integrating advanced genetic engineering with clinical insights, Double Wings Original aims to provide more durable and effective treatment options for patients with refractory cancers.